CareDx counsel sells 2,688 shares under 10b5-1 plan

CareDx, Inc. reports that Secretary and General Counsel Jeffrey Adam Novack sold a total of 2,688 shares of common stock on August 5, 2026, in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025.

Rhea-AI Filing Summary

CareDx, Inc. reports that Secretary and General Counsel Jeffrey Adam Novack sold a total of 2,688 shares of common stock on August 5, 2026, in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. The sales comprised 2,188 shares at a weighted average price of $46.1492 (range $45.49–$46.45) and 500 shares at $46.75 (range $46.59–$46.94).

Insider Trade Summary 10b5-1

Net Seller: 2,688 shares

Net Sell 2 txns

Insider Novack Jeffrey Adam

Role Secretary and General Counsel

Sold 2,688 shs ($124K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,188	$46.1492	$101K
Sale	Common Stock F1, F3	500	$46.75	$23K

Holdings After Transaction: Common Stock — 106,075 shares (Direct)

Footnotes (3)

1. F1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on September 4, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.49 to $46.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.59 to $46.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold (first tranche): 2,188 shares Sale price (first tranche): $46.1492 per share Shares sold (second tranche): 500 shares +1 more

4 metrics

Shares sold (first tranche) 2,188 shares Common stock sold on August 5, 2026 at weighted average price $46.1492

Sale price (first tranche) $46.1492 per share Weighted average price; individual trades ranged from $45.49 to $46.45

Shares sold (second tranche) 500 shares Common stock sold on August 5, 2026 at $46.75 per share

Total shares sold 2,688 shares Aggregate common shares sold across both reported transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction market

"Transaction code S: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share sales did CareDx (CDNA) report for Jeffrey Adam Novack?

CareDx (CDNA) reported that Jeffrey Adam Novack sold a total of 2,688 shares of common stock on August 5, 2026. The transactions were reported as open-market or private sales of CareDx common stock by the company’s Secretary and General Counsel.

Were the CareDx (CDNA) insider sales made under a Rule 10b5-1 trading plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan adopted by Jeffrey Adam Novack on September 4, 2025. Each reported transaction cites this trading plan, indicating the trades followed pre-established instructions rather than discretionary timing.

At what prices were the CareDx (CDNA) shares sold by Jeffrey Adam Novack?

One block of shares was sold at a weighted average price of $46.1492, with trades from $45.49 to $46.45. A second block was sold at $46.75 per share, with individual trades ranging from $46.59 to $46.94.

How many separate transactions did the CareDx (CDNA) Form 4 report for Jeffrey Adam Novack?

The Form 4 lists two separate sale transactions on August 5, 2026. The first covered 2,188 shares and the second covered 500 shares, for a combined total of 2,688 shares of CareDx common stock sold.

What is Jeffrey Adam Novack’s role at CareDx (CDNA)?

Jeffrey Adam Novack serves as CareDx’s Secretary and General Counsel. The reported transactions therefore reflect stock sales by a senior legal and corporate officer of CareDx, rather than by an outside director or large institutional shareholder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 04:06 PM Accepted by SEC EDGAR 08/06/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Novack Jeffrey Adam

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD, 4TH FLOOR

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Secretary and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2026		S(1)		2,188	D	$46.1492(2)	106,575	D
Common Stock	08/05/2026		S(1)		500	D	$46.75(3)	106,075	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on September 4, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.49 to $46.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.59 to $46.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Jeffrey Adam Novack	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)